A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

September 25, 2025

Study Completion Date

August 31, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

Placebo

Subcutaneous injection

DRUG

Lebrikizumab

Subcutaneous injection

DRUG

Topical Corticosteroid

Topical Corticosteroid

Trial Locations (46)

15355

Korea University Ansan Hospital, Ansan-si

21431

The Catholic University of Korea, Incheon St. Mary's Hospital, Bupyeong-gu

100029

China-Japan Friendship Hospital, Beijing

100034

Peking University People's Hospital, Beijing

100045

Beijing Children's hospital, Capital Medical University, Beijing

100050

Beijing Friendship Hospital Affiliate of Capital University, Beijing

100091

Peking University Third Hospital, Beijing

100730

Beijing Tongren Hospital affiliated to Capital Medical University, Beijing

102202

Beijing Tsinghua Changgung Hospital, Beijing

130000

The Second Hospital of Jilin University, Changchun

130021

The First Hospital of Jilin University, Changchun

200030

Shanghai Sixth People's Hospital, Shanghai

200040

Huashan Hospital, Fudan University, Shanghai

200071

Shanghai Skin Disease Hospital, Shanghai

200072

Shanghai Tenth People's Hospital, Shanghai

212000

Affiliated Hospital of Jiangsu University, Zhenjiang

214000

Wuxi No.2 People's Hospital, Wuxi

215006

The First Affiliated Hospital of Soochow University, Suzhou

241001

Wannan Medical College Yijishan Hospital, Wuhu

300052

Tianjin Medical University General Hospital, Tianjin

310000

The First People's Hospital of Hangzhou, Hangzhou

310003

The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310016

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou

322000

Zhejiang University School of Medicine - The Fourth Affiliated Hospital, Yiwu

350005

The First Affiliated Hospital Of Fujian Medical University, Fuzhou

361015

Zhongshan Hospital Fudan University (Xiamen Branch), Xiamen

400065

The Children's Hospital of Chongqing Medical University, Chongqing

410007

Hunan Children's Hospital, Changsha

410008

Xiangya Hospital Central South University, Changsha

410011

The Second Xiangya Hospital of Central South University, Changsha

430022

The First Hospital of Wuhan, Wuhan

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

510018

Guangdong Province Dermatology Hospital, Guangzhou

510180

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

518026

Shenzhen Children's Hospital, Shenzhen

518036

Peking University Shenzhen Hospital, Shenzhen

518053

The University of Hong Kong-Shenzhen Hospital, Shenzhen

570311

Hainan General Hospital, Haikou

610041

West China Hospital, Sichuan University, Chengdu

710004

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

050031

The First Hospital of Hebei Medical University, Shijiazhuang

030013

Children's Hospital of Shanxi, Taiyuan

01812

National Medical Center, Seoul

05505

Asan Medical Center, Seoul

07441

Hallym University Kangnam Sacred Heart Hospital, Seoul

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06280716 - A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter